Price$0.37+0.01 (+2.67%)
02:30 PM07:30 PM
News · 26 weeks240%
2025-12-142026-06-07
Mix890d
- Other3(38%)
- SEC Filings3(38%)
- Insider2(25%)
Latest news
25 items- SECSEC Form 10-Q filed by Mangoceuticals Inc.10-Q - MANGOCEUTICALS, INC. (0001938046) (Filer)
- SECSEC Form NT 10-Q filed by Mangoceuticals Inc.NT 10-Q - MANGOCEUTICALS, INC. (0001938046) (Filer)
- SECSEC Form 10-K filed by Mangoceuticals Inc.10-K - MANGOCEUTICALS, INC. (0001938046) (Filer)
- SECSEC Form NT 10-K filed by Mangoceuticals Inc.NT 10-K - MANGOCEUTICALS, INC. (0001938046) (Filer)
- INSIDERSEC Form 4 filed by Cohen Jacob D.4 - MANGOCEUTICALS, INC. (0001938046) (Issuer)
- INSIDERSEC Form 4 filed by Cohen Jacob D.4 - MANGOCEUTICALS, INC. (0001938046) (Issuer)
- SECMangoceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - MANGOCEUTICALS, INC. (0001938046) (Filer)
- PRMangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.Dallas, Texas, March 17, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("Mangoceuticals," the "Company," or "MangoRx"), a company focused on developing, marketing, and selling health and wellness products through a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced that it has filed a civil lawsuit against Clarity Ventures, Inc., its former technology consulting and software development firm ("Clarity"). The lawsuit, filed in Texas state court, seeks damages exceeding $73 million, exclusive of interest, costs, and attorneys' fees. The Company alleges that Clarity failed to deliver a fully functional, HIPAA-compliant enterprise resource plann
- PRMangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or BirdsDallas, TX, March 06, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, and a pioneer in innovative wellness solutions and its partner IntraMont Technologies, Inc. today announced the filing of a Patent Cooperation Treaty (PCT) international application (P-641039-PC) on February 26, 2026, to secure broad global patent protection for the antiviral animal feed and drinking water additive technology that powers MGX-0024. This PCT filing directly extends the intellectual property portfolio supporting the results
- SECMangoceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - MANGOCEUTICALS, INC. (0001938046) (Filer)
- PRMangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government StudyDallas, TX, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, and a pioneer in innovative wellness solutions, today announced new data from its proprietary antiviral compound MGX-0024. A technical report issued by partner IntraMont Technologies in late 2025, combined with the final signed report from the ICAR-National Institute of High Security Animal Diseases (NIHSAD), Bhopal, supports MGX-0024's potential to reduce respiratory disease impacts in commercial poultry settings and provide meaningful ea
- SECMangoceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - MANGOCEUTICALS, INC. (0001938046) (Filer)
- PRMangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment ProgramMonth over Month Growth of 336% and 54% Reduction in Customer Acquisition Cost (CAC) DALLAS, TX, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (the "Company" or "MangoRx"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced that MangoRx has experienced initial success for its newly launched all-inclusive injectable Testosterone Replacement Therapy (TRT) treatment program priced at $99 per month. The new TRT offer includes all doctor visits and medical consultations, lab work and analysis, and the medication to the extent prescribe
- SECMangoceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - MANGOCEUTICALS, INC. (0001938046) (Filer)
- SECSEC Form EFFECT filed by Mangoceuticals Inc.EFFECT - MANGOCEUTICALS, INC. (0001938046) (Filer)
- SECAmendment: SEC Form S-1/A filed by Mangoceuticals Inc.S-1/A - MANGOCEUTICALS, INC. (0001938046) (Filer)
- SECSEC Form S-1 filed by Mangoceuticals Inc.S-1 - MANGOCEUTICALS, INC. (0001938046) (Filer)
- PRMangoceuticals, Inc. Announces Closing of $2.5 Million Registered Direct and Private PlacementsDALLAS, TX, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (the "Company"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced the closing of its previously announced registered direct offering and concurrent private placement with institutional investors. The Company issued shares of Common Stock and pre-funded warrants in a registered direct offering. In a concurrent private placement, the Company also issued to the same investors investor warrants. Aggregate gross proceeds to the Company from both transactions were approximately
- SECMangoceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - MANGOCEUTICALS, INC. (0001938046) (Filer)
- SECSEC Form 424B5 filed by Mangoceuticals Inc.424B5 - MANGOCEUTICALS, INC. (0001938046) (Filer)
- SECMangoceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - MANGOCEUTICALS, INC. (0001938046) (Filer)
- PRMangoceuticals, Inc. Announces Partnership with The Cube Group to Launch Up To $100 Million Solana-Focused Digital Asset Treasury (DAT) StrategyMULTI-DAT Framework Drives Diversified Crypto Expansion and Volatility Hedging DALLAS, TX, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (the "Company"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced an up to $100 million Solana-focused digital asset treasury (DAT) strategy in partnership with Cube Group, through its newly formed subsidiary, Mango DAT, LLC. This initiative positions Mangoceuticals at the forefront of institutional adoption in the Solana ecosystem, leveraging high-yield opportunities to drive sustainable, non
- PRMangoceuticals, Inc. Announces $2.5 Million Registered Direct and Private Placements Priced at the Market Under Nasdaq RulesDALLAS, TX, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (the "Company"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of shares of Common Stock and pre-funded warrants in a registered direct offering. In a concurrent private placement, the Company also agreed to sell to the same investors investor warrants. Aggregate gross proceeds to the Company from both transactions are expected to be approximately $2.5 million. The enti
- INSIDERCFO Johnston Eugene M sold $3,884 worth of shares (3,333 units at $1.17), decreasing direct ownership by 3% to 120,000 units (SEC Form 4)4 - MANGOCEUTICALS, INC. (0001938046) (Issuer)
- INSIDERCFO Johnston Eugene M sold $5,975 worth of shares (5,000 units at $1.20), decreasing direct ownership by 4% to 123,333 units (SEC Form 4)4 - MANGOCEUTICALS, INC. (0001938046) (Issuer)
MGRX FAQ
5 questionsWhere does MGRX stock trade?
Mangoceuticals Inc. (MGRX) is listed on NASDAQ.What sector and industry is MGRX in?
Mangoceuticals Inc. operates in the Health Care sector, Misc Health and Biotechnology Services industry.When did Mangoceuticals Inc. go public?
Mangoceuticals Inc. (MGRX) completed its IPO in 2023.What companies are similar to MGRX?
Notable peers in the same industry include DVA (DaVita Inc.), FMS (Fresenius Medical Care AG), SHC (Sotera Health Company), PGNY (Progyny Inc.), AGL (agilon health inc.). Compare MGRX side-by-side with any of them on Quantisnow.How can I track MGRX on Quantisnow?
Quantisnow aggregates Mangoceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MGRX to receive live email and push alerts on every new disclosure.